BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y.L. Lui, Carla Grandori, Kay E. Gurley et al.|EBioMedicine|2020Cited by 38
Abstract 534: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilitiesGoldie Y.L. Lui, Carla Grandori, Anne B. Richardson et al.|Cancer Research|2021Cited by 4